Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis and Metrics

Recursion Pharmaceuticals

NASDAQ: RXRX

$2.96 ▼ -0.05 (-1.50%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.57 Bn

P/E-2.81

P/S23.67

Div. Yield0.00

ROIC (Qtr)-0.16

Total Debt (Qtr)16.45 Mn

Revenue Growth (1y) (Qtr)-56.11

Add ratio to table…

About

Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company focused on decoding biology to improve lives. The company has built an integrated drug discovery and development platform called the Recursion Operating System (OS). This platform combines large scale biological data generation, artificial intelligence driven chemistry design, and clinical development tools to move ideas from the lab to the clinic. By using automation and AI, Recursion aims to reduce the time and cost traditionally associated with bringing new medicines to patients. The OS works across three stages: first it generates detailed cellular images and molecular data, then it uses those data to design potential drug molecules, and finally it supports the planning and execution of clinical studies. This end to end approach allows the company to test many hypotheses quickly and to prioritize the most promising candidates for further development.

Recursion generates revenue primarily through strategic collaborations with pharmaceutical partners. The company receives upfront cash payments, milestone payments as programs advance, and is eligible for tiered royalties on future product sales. To date it has secured over five hundred million dollars in upfront and milestone payments from collaborations with Roche and Genentech, Sanofi, Bayer and Merck KGaA. Specific agreements include an upfront payment of one hundred fifty million dollars from Roche and Genentech, an upfront payment of one hundred million dollars from Sanofi, and an upfront payment of twenty million dollars from Merck KGaA. These partnerships also provide the potential for more than twenty billion dollars in additional milestones before royalties are paid. Recursion does not currently sell commercial products, so its revenue comes exclusively from these partnership activities.

Recursion occupies a distinctive place in the drug discovery industry as a technology driven biotech firm. Its main competitors include other TechBio companies such as Relay Therapeutics, Isomorphic Labs, Schrödinger and AbCellera, as well as large pharmaceutical firms that are increasingly adopting artificial intelligence in their research. The company’s competitive advantage stems from its proprietary data set of over fifty petabytes, its in house supercomputer BioHive 2, and its bilingual teams that blend expertise in biology and data science. This infrastructure enables the platform to synthesize far fewer compounds per program, approximately three hundred thirty compared with the industry average of two thousand five hundred, while maintaining high quality candidates. In addition, the OS uses machine learning models that are continuously updated with new experimental data, which improves the accuracy of predictions about drug behavior. These factors give Recursion a potential edge in efficiency and success rates, helping it to advance programs with lower attrition than traditional methods.

The company’s customers are primarily large pharmaceutical and biotechnology firms with which it collaborates. Current partners include Roche and Genentech, Sanofi, Bayer and Merck KGaA. Through these relationships, Recursion provides data, chemistry and clinical development services that help partners identify and advance therapeutic candidates. The company does not have direct sales to patients or consumers at this stage of development. While the company’s ultimate goal is to deliver medicines to patients, its present revenue base consists of these corporate collaborators.

Investment Thesis

▲ Bull case

Recursion Pharmaceuticals is positioned to capture significant value from its AI-native platform as it transitions from proof-of-concept to tangible clinical and commercial outcomes, with the REC-4881 program in FAP representing a near-term inflection point that the market is underestimating. The company has already demonstrated compelling Phase II proof of concept, showing significant reduction in precancerous polyps and durability of effect in a patient population with no existing therapeutic options and near-inevitable colorectal cancer risk. Management has initiated FDA engagement to define a registrational path, leveraging the rare disease framework and natural history study data to derisk the pivotal trial design—a process they are ahead of schedule on. With multiple wholly-owned programs (REC-1245, REC-4539, and others) expected to deliver clinical readouts over the next 12–18 months, the company is building a consistent cadence of catalysts that could de-risk its platform validity beyond a single asset. The market may be overlooking how REC-4881’s durability of response, a rare feature in MEK inhibitor data, could support accelerated approval pathways and premium pricing in a niche but underserved indication, potentially establishing a foothold for broader oncology applications of its AI-driven target discovery engine.
The strategic value of Recursion’s partnerships, particularly with Sanofi and Roche/Genentech, is being underappreciated as a source of non-dilutive validation and optionality, with recent milestone progress signaling imminent development candidate decisions that could unlock substantial near-term economics. Over $500 million in partner inflows and 10 milestones delivered to date reflect a track record of executing on complex collaborations, yet the market may not be fully pricing in the probability of clinical opt-ins from partners on AI-designed compounds for historically undruggable targets in immunology and oncology. The Sanofi collaboration, focused on using Recursion’s chemistry AI to tackle challenging protein targets, is progressing toward development candidate selection within the next 12–18 months—a critical juncture where successful translation could trigger option exercises and milestone payments. Similarly, the Roche/Genentech alliance leverages Recursion’s biology perturbation maps and foundation models to convert large-scale multimodal data into validated, first-in-class programs, with a potential first such program expected within the same timeframe. These partnerships not only de-risk the platform’s technological validity but also create asymmetric upside: if partners opt in, Recursion retains downstream economics while avoiding the full cost of clinical development, effectively transforming its platform into a recurring revenue engine.
Recursion’s platform efficiency gains—evidenced by synthesizing 90% fewer compounds than industry benchmarks while advancing candidates twice as fast—are translating into a sustainable competitive moat that the market is failing to fully appreciate as a driver of long-term margin expansion and capital efficiency. The deployment of foundation models like TxPert and TxFM, which outperform models trained on 100x larger datasets due to superior data curation and architecture, is reducing experimental noise and enabling mechanistic insights that directly inform clinical trial design, patient stratification, and target selection. This is not merely incremental improvement; it represents a step-change in the ability to generalize biological predictions to out-of-distribution contexts (novel targets, combinations, cell types), a critical advantage in drug discovery where failure rates remain high due to poor translational validity. By integrating wet and dry labs with purpose-built AI models and bilingual talent, Recursion is building a closed-loop system that continuously learns and improves—turning its platform into a self-reinforcing engine of innovation. The market may be underestimating how these efficiencies compound over time: lower attrition, faster cycle times, and higher success rates in candidate selection could significantly reduce the cost per approved drug, ultimately translating into superior ROIC compared to traditional biotech peers as the platform scales.

Recursion Pharmaceuticals is positioned to capture significant value from its AI-native platform as it transitions from proof-of-concept to tangible clinical and commercial outcomes, with the REC-4881 program in FAP representing a near-term inflection point that the market is underestimating. The company has already demonstrated compelling Phase II proof of concept, showing significant reduction in precancerous polyps and durability of effect in a patient population with no existing therapeutic options and near-inevitable colorectal cancer risk. Management has initiated FDA engagement to define a registrational path, leveraging the rare disease framework and natural history study data to derisk the pivotal trial design—a process they are ahead of schedule on. With multiple wholly-owned programs (REC-1245, REC-4539, and others) expected to deliver clinical readouts over the next 12–18 months, the company is building a consistent cadence of catalysts that could de-risk its platform validity beyond a single asset. The market may be overlooking how REC-4881’s durability of response, a rare feature in MEK inhibitor data, could support accelerated approval pathways and premium pricing in a niche but underserved indication, potentially establishing a foothold for broader oncology applications of its AI-driven target discovery engine.
The strategic value of Recursion’s partnerships, particularly with Sanofi and Roche/Genentech, is being underappreciated as a source of non-dilutive validation and optionality, with recent milestone progress signaling imminent development candidate decisions that could unlock substantial near-term economics. Over $500 million in partner inflows and 10 milestones delivered to date reflect a track record of executing on complex collaborations, yet the market may not be fully pricing in the probability of clinical opt-ins from partners on AI-designed compounds for historically undruggable targets in immunology and oncology. The Sanofi collaboration, focused on using Recursion’s chemistry AI to tackle challenging protein targets, is progressing toward development candidate selection within the next 12–18 months—a critical juncture where successful translation could trigger option exercises and milestone payments. Similarly, the Roche/Genentech alliance leverages Recursion’s biology perturbation maps and foundation models to convert large-scale multimodal data into validated, first-in-class programs, with a potential first such program expected within the same timeframe. These partnerships not only de-risk the platform’s technological validity but also create asymmetric upside: if partners opt in, Recursion retains downstream economics while avoiding the full cost of clinical development, effectively transforming its platform into a recurring revenue engine.
Recursion’s platform efficiency gains—evidenced by synthesizing 90% fewer compounds than industry benchmarks while advancing candidates twice as fast—are translating into a sustainable competitive moat that the market is failing to fully appreciate as a driver of long-term margin expansion and capital efficiency. The deployment of foundation models like TxPert and TxFM, which outperform models trained on 100x larger datasets due to superior data curation and architecture, is reducing experimental noise and enabling mechanistic insights that directly inform clinical trial design, patient stratification, and target selection. This is not merely incremental improvement; it represents a step-change in the ability to generalize biological predictions to out-of-distribution contexts (novel targets, combinations, cell types), a critical advantage in drug discovery where failure rates remain high due to poor translational validity. By integrating wet and dry labs with purpose-built AI models and bilingual talent, Recursion is building a closed-loop system that continuously learns and improves—turning its platform into a self-reinforcing engine of innovation. The market may be underestimating how these efficiencies compound over time: lower attrition, faster cycle times, and higher success rates in candidate selection could significantly reduce the cost per approved drug, ultimately translating into superior ROIC compared to traditional biotech peers as the platform scales.

▼ Bear case

Recursion Pharmaceuticals faces significant execution risk in translating its AI platform insights into clinically meaningful and commercially viable medicines, with the REC-4881 program in FAP exemplifying the uncertainty inherent in pioneering first-in-disease therapies where regulatory pathways remain undefined and clinical durability is unproven at scale. While early Phase II data showed polyp burden reduction and signals of durability, the company has not yet disclosed depth of response, duration of effect beyond the observed period, or impact on hard clinical endpoints like colorectal cancer incidence or mortality—critical gaps for a preventive therapy in a genetic disorder. Management’s reliance on the rare disease framework and natural history data to define clinically meaningful endpoints introduces subjectivity and regulatory risk, as the FDA may demand more robust validation of surrogate endpoints given the lack of precedent for MEK inhibition in FAP. Furthermore, the ongoing dose escalation in REC-1245 and REC-4539 trials, coupled with the acknowledgment that hematologic toxicity (a known concern with RBM39 degradation and LSD1 inhibition) remains under active monitoring, suggests that early safety signals may not predict long-term tolerability, particularly in chronic dosing regimens required for cancer or premalignant conditions. The market may be overestimating the near-term predictability of clinical success given the biological complexity of splicing fidelity and epigenetic targets, where on-mechanism toxicities have historically derailed promising candidates.
The company’s platform efficiency claims—such as synthesizing 90% fewer compounds and advancing candidates twice as fast—lack sufficient independent validation and may reflect optimistic internal benchmarks rather than industry-wide superiority, raising concerns about the scalability and generalizability of its AI-driven advantages across diverse target classes. While Recursion highlights progress in foundation models like TxPert and TxFM, the clinical translation of these tools remains unproven; there is no evidence yet that reduced compound synthesis or faster preclinical timelines have led to higher clinical success rates or better therapeutic indices in human trials. The dependence on proprietary data and custom model architecture creates a potential moat, but also a black box risk: if the underlying data quality or model assumptions are flawed, the entire platform’s predictive power could be illusory, leading to costly late-stage failures. Additionally, the emphasis on “bilingual talent” and cultural integration, while important, does not guarantee operational excellence in clinical development—a domain where Recursion is still building expertise, as evidenced by the recent hire of a new CMO with limited tenure. The market may be ignoring the high failure rate inherent in AI-driven drug discovery, where algorithmic predictions frequently fail to account for biological complexity, resulting in compounds that look promising in silico or in vitro but lack efficacy or safety in vivo.
Recursion’s financial runway, while stated to extend into early 2028, is contingent on maintaining a 30% year-over-year reduction in operating expenses—a target that may become increasingly difficult to sustain as the company advances multiple clinical programs and incurs rising costs associated with trial execution, manufacturing, and regulatory preparation. The guidance of less than $390 million in cash operating expenses for 2026 assumes continued efficiency gains from technology adoption and infrastructure simplification, yet these savings may be offset by the inevitable cost inflation of scaling clinical activities across its broadening pipeline. With over $500 million in partner inflows to date, the company has demonstrated success in securing upfront and milestone payments, but the long-term value of these partnerships hinges on partners exercising opt-in rights—a decision that remains uncertain and could leave Recursion bearing the full burden of development costs if partnerships do not mature. Furthermore, the company’s reliance on partner-derived economics to complement its wholly-owned pipeline creates a vulnerability: if partner programs stall or fail to deliver candidates, the anticipated near-term catalysts could dissipate, forcing greater reliance on internal programs that are still early-stage and unproven. The market may be overlooking how the combination of rising clinical costs, uncertain partner opt-ins, and the need to fund multiple simultaneous trials could strain liquidity sooner than anticipated, potentially necessitating dilutive financing before the projected 2028 runway.

Recursion Pharmaceuticals faces significant execution risk in translating its AI platform insights into clinically meaningful and commercially viable medicines, with the REC-4881 program in FAP exemplifying the uncertainty inherent in pioneering first-in-disease therapies where regulatory pathways remain undefined and clinical durability is unproven at scale. While early Phase II data showed polyp burden reduction and signals of durability, the company has not yet disclosed depth of response, duration of effect beyond the observed period, or impact on hard clinical endpoints like colorectal cancer incidence or mortality—critical gaps for a preventive therapy in a genetic disorder. Management’s reliance on the rare disease framework and natural history data to define clinically meaningful endpoints introduces subjectivity and regulatory risk, as the FDA may demand more robust validation of surrogate endpoints given the lack of precedent for MEK inhibition in FAP. Furthermore, the ongoing dose escalation in REC-1245 and REC-4539 trials, coupled with the acknowledgment that hematologic toxicity (a known concern with RBM39 degradation and LSD1 inhibition) remains under active monitoring, suggests that early safety signals may not predict long-term tolerability, particularly in chronic dosing regimens required for cancer or premalignant conditions. The market may be overestimating the near-term predictability of clinical success given the biological complexity of splicing fidelity and epigenetic targets, where on-mechanism toxicities have historically derailed promising candidates.
The company’s platform efficiency claims—such as synthesizing 90% fewer compounds and advancing candidates twice as fast—lack sufficient independent validation and may reflect optimistic internal benchmarks rather than industry-wide superiority, raising concerns about the scalability and generalizability of its AI-driven advantages across diverse target classes. While Recursion highlights progress in foundation models like TxPert and TxFM, the clinical translation of these tools remains unproven; there is no evidence yet that reduced compound synthesis or faster preclinical timelines have led to higher clinical success rates or better therapeutic indices in human trials. The dependence on proprietary data and custom model architecture creates a potential moat, but also a black box risk: if the underlying data quality or model assumptions are flawed, the entire platform’s predictive power could be illusory, leading to costly late-stage failures. Additionally, the emphasis on “bilingual talent” and cultural integration, while important, does not guarantee operational excellence in clinical development—a domain where Recursion is still building expertise, as evidenced by the recent hire of a new CMO with limited tenure. The market may be ignoring the high failure rate inherent in AI-driven drug discovery, where algorithmic predictions frequently fail to account for biological complexity, resulting in compounds that look promising in silico or in vitro but lack efficacy or safety in vivo.
Recursion’s financial runway, while stated to extend into early 2028, is contingent on maintaining a 30% year-over-year reduction in operating expenses—a target that may become increasingly difficult to sustain as the company advances multiple clinical programs and incurs rising costs associated with trial execution, manufacturing, and regulatory preparation. The guidance of less than $390 million in cash operating expenses for 2026 assumes continued efficiency gains from technology adoption and infrastructure simplification, yet these savings may be offset by the inevitable cost inflation of scaling clinical activities across its broadening pipeline. With over $500 million in partner inflows to date, the company has demonstrated success in securing upfront and milestone payments, but the long-term value of these partnerships hinges on partners exercising opt-in rights—a decision that remains uncertain and could leave Recursion bearing the full burden of development costs if partnerships do not mature. Furthermore, the company’s reliance on partner-derived economics to complement its wholly-owned pipeline creates a vulnerability: if partner programs stall or fail to deliver candidates, the anticipated near-term catalysts could dissipate, forcing greater reliance on internal programs that are still early-stage and unproven. The market may be overlooking how the combination of rising clinical costs, uncertain partner opt-ins, and the need to fund multiple simultaneous trials could strain liquidity sooner than anticipated, potentially necessitating dilutive financing before the projected 2028 runway.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password